About arbutus biopharma - ABUS
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
ABUS At a Glance
Arbutus Biopharma Corp.
701 Veterans Circle
Warminster, Pennsylvania 18974
| Phone | 1-267-469-0914 | Revenue | 14.08M | |
| Industry | Pharmaceuticals: Major | Net Income | -33,501,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 128.213% | |
| Fiscal Year-end | 12 / 2026 | Employees | 19 | |
| View SEC Filings |
ABUS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 65.44 |
| Price to Book Ratio | 12.094 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -31.262 |
| Enterprise Value to Sales | 59.242 |
| Total Debt to Enterprise Value | 0.005 |
ABUS Efficiency
| Revenue/Employee | 741,210.526 |
| Income Per Employee | -1,763,210.526 |
| Receivables Turnover | 8.061 |
| Total Asset Turnover | 0.124 |
ABUS Liquidity
| Current Ratio | 15.727 |
| Quick Ratio | 15.727 |
| Cash Ratio | 15.23 |
ABUS Profitability
| Gross Margin | 97.422 |
| Operating Margin | -192.083 |
| Pretax Margin | -237.883 |
| Net Margin | -237.883 |
| Return on Assets | -29.604 |
| Return on Equity | -38.52 |
| Return on Total Capital | -41.48 |
| Return on Invested Capital | -36.57 |
ABUS Capital Structure
| Total Debt to Total Equity | 5.469 |
| Total Debt to Total Capital | 5.185 |
| Total Debt to Total Assets | 4.426 |
| Long-Term Debt to Equity | 4.755 |
| Long-Term Debt to Total Capital | 4.508 |